Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0271650
Disease: Impaired glucose tolerance
Impaired glucose tolerance 		0.310 Biomarker phenotype BEFREE Furthermore, METRNL administration rescued glucose intolerance and reduced HFD-induced body weight gain in mice; however, METRNL did not affect calorie intake. 30213948 2018
CUI: C0271650
Disease: Impaired glucose tolerance
Impaired glucose tolerance 		0.310 Therapeutic phenotype CTD_human Furthermore, METRNL administration rescued glucose intolerance and reduced HFD-induced body weight gain in mice; however, METRNL did not affect calorie intake. 30213948 2018
CUI: C0021655
Disease: Insulin Resistance
Insulin Resistance 		0.300 Therapeutic phenotype CTD_human In the current study, we report for the first time that METRNL alleviates inflammation and insulin resistance and induces fatty acid oxidation through AMPK or PPARδ-dependent signaling in skeletal muscle. 30213948 2018
CUI: C0043094
Disease: Weight Gain
Weight Gain 		0.300 Therapeutic phenotype CTD_human Furthermore, METRNL administration rescued glucose intolerance and reduced HFD-induced body weight gain in mice; however, METRNL did not affect calorie intake. 30213948 2018
CUI: C0920563
Disease: Insulin Sensitivity
Insulin Sensitivity 		0.300 Therapeutic phenotype CTD_human METRNL attenuates lipid-induced inflammation and insulin resistance via AMPK or PPARδ-dependent pathways in skeletal muscle of mice. 30213948 2018
CUI: C0023893
Disease: Liver Cirrhosis, Experimental
Liver Cirrhosis, Experimental 		0.300 Biomarker disease CTD_human Systems level analysis and identification of pathways and networks associated with liver fibrosis. 25380136 2014
CUI: C0042834
Disease: Vital capacity
Vital capacity 		0.100 GeneticVariation phenotype GWASCAT Leveraging Polygenic Functional Enrichment to Improve GWAS Power. 30595370 2019
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.030 Biomarker disease BEFREE A decrease in the serum Subfatin in T2DM patients and prediabetes subjects, and its association with vascular adhesion molecules suggested the possible role of Subfatin in diabetes and endothelial dysfunction. 30463448 2018
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.030 AlteredExpression disease BEFREE Lower serum levels of Meteorin-like/Subfatin in patients with coronary artery disease and type 2 diabetes mellitus are negatively associated with insulin resistance and inflammatory cytokines. 30212581 2018
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.030 AlteredExpression disease BEFREE Serum Meteorin-like protein levels decreased in patients newly diagnosed with type 2 diabetes. 29097285 2018
CUI: C0028754
Disease: Obesity
Obesity 		0.020 Biomarker disease BEFREE Aerobic Exercise Increases Meteorin-Like Protein in Muscle and Adipose Tissue of Chronic High-Fat Diet-Induced Obese Mice. 29854769 2018
CUI: C0028754
Disease: Obesity
Obesity 		0.020 Biomarker disease BEFREE Subfatin is a novel adipokine regulated by adipogenesis and obesity, with tissue distribution different from its homologue Meteorin. 24393292 2014
CUI: C0010054
Disease: Coronary Arteriosclerosis
Coronary Arteriosclerosis 		0.010 AlteredExpression disease BEFREE Lower serum levels of Meteorin-like/Subfatin in patients with coronary artery disease and type 2 diabetes mellitus are negatively associated with insulin resistance and inflammatory cytokines. 30212581 2018
CUI: C0010068
Disease: Coronary heart disease
Coronary heart disease 		0.010 AlteredExpression disease BEFREE Lower serum levels of Meteorin-like/Subfatin in patients with coronary artery disease and type 2 diabetes mellitus are negatively associated with insulin resistance and inflammatory cytokines. 30212581 2018
CUI: C0362046
Disease: Prediabetes syndrome
Prediabetes syndrome 		0.010 Biomarker disease BEFREE A decrease in the serum Subfatin in T2DM patients and prediabetes subjects, and its association with vascular adhesion molecules suggested the possible role of Subfatin in diabetes and endothelial dysfunction. 30463448 2018
CUI: C0856169
Disease: Endothelial dysfunction
Endothelial dysfunction 		0.010 Biomarker phenotype BEFREE A decrease in the serum Subfatin in T2DM patients and prediabetes subjects, and its association with vascular adhesion molecules suggested the possible role of Subfatin in diabetes and endothelial dysfunction. 30463448 2018
CUI: C1956346
Disease: Coronary Artery Disease
Coronary Artery Disease 		0.010 AlteredExpression disease BEFREE Lower serum levels of Meteorin-like/Subfatin in patients with coronary artery disease and type 2 diabetes mellitus are negatively associated with insulin resistance and inflammatory cytokines. 30212581 2018
CUI: C0028259
Disease: Nodule
Nodule 		0.010 AlteredExpression phenotype BEFREE Overexpression of METRNL inhibited mineralized nodule formation by the MG63 osteosarcoma cell line. 27716826 2016
CUI: C0029463
Disease: Osteosarcoma
Osteosarcoma 		0.010 AlteredExpression disease BEFREE Overexpression of METRNL inhibited mineralized nodule formation by the MG63 osteosarcoma cell line. 27716826 2016
CUI: C0585442
Disease: Osteosarcoma of bone
Osteosarcoma of bone 		0.010 AlteredExpression disease BEFREE Overexpression of METRNL inhibited mineralized nodule formation by the MG63 osteosarcoma cell line. 27716826 2016
CUI: C1332986
Disease: Childhood Osteosarcoma
Childhood Osteosarcoma 		0.010 AlteredExpression disease BEFREE Overexpression of METRNL inhibited mineralized nodule formation by the MG63 osteosarcoma cell line. 27716826 2016
CUI: C1258666
Disease: Myxoid cyst
Myxoid cyst 		0.010 Biomarker disease BEFREE During early mouse development, Cometin is found exclusively in the floor plate and from E13.5 also in dorsal root ganglions and inner ear but apparently not in the adult nervous system. 21985865 2012